Skip to main content
300 Collins St Melbourne hello@pivot.net
Login Signup
Home Home

Main navigation

  • About
    • Senior Management
    • Leadership
    • Board of Directors
    • Advisors
    • Contact
  • Research & Development
    • Innovation Engine
    • Therapeutic Focus
    • Development Strategy
    • Scientific Presentations
  • Pipeline
    • RMC-4630 (SHP2)
    • RMC-5552 (mTORC1/4EBP1)
    • SOS1
    • RAS(ON) Inhibitors
    • EXPANDED ACCESS POLICY
  • Investors
  • Careers

Drugging the RAS(ON) Form of Diverse Oncogenic RAS Mutations

February 25, 2021

Steve Kelsey

 

Digital RAS- Targeted Drug Discovery Summit; February 23-25, 2021.

 

Download Presentation
Return to Media Home

Latest Scientific Presentations

Discovery of RMC-5552, a Selective Bi-Steric Inhibitor of mTORC1, for the Treatment of mTORC1-Activated Tumors
Enhancement of anti-tumor immunity in immunogenic and immune-refractory RAS mutant tumors with tri-complex RAS(ON) inhibitors
The Bi-steric mTORC1-Selective Inhibitor RMC-5552 in Tumors with Activation of mTOR Signaling: Preclinical Activity in Combination with RAS(ON) Inhibitors in RAS-Addicted Tumors, and Initial Clinical Findings from A Single Agent Phase 1/1b Study
RMC-6291, a Next-Generation Tri-Complex KRAS-G12C(ON) Inhibitor, Outperforms KRAS-G12C(OFF) Inhibitors in Preclinical Models of KRAS-G12C Cancers
Translating Frontier Oncology Targets to Outsmart RAS-Addicted Cancers
© Revolution Medicines, Inc.  |  700 Saginaw Drive, Redwood City, CA 94063
CCPA Notice | Privacy Policy
Get in touch with us